Caesarea, Israel - LabStyle Innovations Corp., developer of the Dario Diabetes Management Solution, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for core patent claims covering the company’s personalized blood glucose monitoring device.
LabStyle’s now patent pending invention, entitled “Fluid Testing Apparatus And Methods of Use,” specifically relates to how the Dario blood glucose monitor draws power from and transmits data to a smart phone via the audio jack port. This device is designed to work in tandem with LabStyle’s novel and powerful Dario software application to form the overall Dario Diabetes Management Solution.
The issuance of the Notice of Allowance is the critical milestone that will allow LabStyle to obtain formal U.S. patent protection in the coming months for this invention while LabStyle continues to seek similar patent protection in non-U.S. jurisdictions. LabStyle also believes that the claims of this invention could potentially be expanded to cover the measurement of other physiological parameters.
“This is a major milestone for our company and an important recognition of the truly novel nature of our Dario product offering. Dario is the world’s first personalized smart meter and is already changing the way people manage their diabetes in our initial launch jurisdictions. This patent allowance validates our efforts in developing cutting edge products that help people manage their diabetes and thrive. Further, this patent will greatly strengthen our competitive position in the U.S. assuming FDA approval of Dario. Importantly, the allowed claims underscore our ownership of this technology and cover our methodology that has been based upon our extensive database of reference feedback, close customer collaboration, and innovative product engineering and development. We’re extremely proud to have achieved this distinction,” said Erez Raphael, president and CEO of LabStyle.
In September 2013, LabStyle received CE mark certification for the Dario personalized smart meter (Dario Blood Glucose Monitoring System) and began a world rollout in select countries. LabStyle filed a Premarket Notification Application, also known as a 510(k), with the US Food and Drug Administration (FDA) for Dario in December 2013 and is expecting a response from FDA later this year.
Source: LabStyle Innovations